PRESS RELEASES


IMPAX NAMES ARTHUR A. KOCH, JR. SENIOR VICE PRESIDENT, FINANCE,
AND CHIEF FINANCIAL OFFICER

HAYWARD, Calif.--(BUSINESS WIRE)--April 1, 2005--IMPAX Laboratories, Inc.
(NASDAQ: IPXL) today announced the appointment of Arthur A. Koch, Jr. as Senior
Vice President, Finance, and Chief Financial Officer, effective immediately,
reporting to the Chief Executive Officer. This completes the transition
following the previously announced retirement of the former CFO, Mr. Cornel
Spiegler, who will become a consultant to the company to assist with a smooth
transition.

"Art has 30 years of finance, operations and public accounting experience,
including service as Chief Financial Officer of three publicly traded
healthcare companies. We are fortunate to add such an accomplished and
well-rounded executive to our management team," said Barry R. Edwards, Chief
Executive Officer of IMPAX. "His financial and capital markets expertise should
prove valuable to our growing company."

For the past seven years of his career, Mr. Koch has been with Strategic
Diagnostics Inc. (NASDAQ: SDIX), a company that develops, manufactures and
markets immunoassay-based diagnostic test kits, including six years as Chief
Operating Officer, five months as interim Chief Executive Officer and five
years as Chief Financial Officer and Vice President. At Strategic Diagnostics,
his most recent responsibilities included responsibility for all P&L activities
and leadership of the research, manufacturing and financial functions. He also
was involved in several acquisitions and developed the company's investor
relations campaign.

Mr. Koch has held further CFO positions at Paracelsian Inc., IBAH Inc., Liberty
Fish Company and Premier Solutions Ltd. In addition, he has served as a
corporate finance and operations consultant for numerous private companies, and
spent the first eight years of his career at KPMG LLP, rising to the rank of
senior manager. Mr. Koch holds a Bachelor of Business Administration from
Temple University and has been a Certified Public Accountant since 1977.

IMPAX Laboratories, Inc. is a technology-based specialty pharmaceutical company
applying its formulation expertise and drug delivery technology to the
development of controlled-release and specialty generics in addition to the
development of branded products. IMPAX markets its generic products through its
Global Pharmaceuticals division and intends to market its branded products
through the IMPAX Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully leverage its
technology platform. IMPAX Laboratories is headquartered in Hayward, Calif.,
and has a full range of capabilities in its Hayward and Philadelphia
facilities. For more information, please visit the Company's Web site at:
www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:

To the extent any statements made in this news release contain information that
is not historical, these statements are forward-looking in nature and express
the beliefs and expectations of management. Such statements are based on
current expectations and involve a number of known and unknown risks and
uncertainties that could cause IMPAX's future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. Such
risks and uncertainties include, but are not limited to, possible adverse
effects resulting from IMPAX's delay in filing its 2004 Form 10-K including
possible delisting from the NASDAQ National Market, IMPAX's ability to obtain
sufficient capital to fund its operations, the difficulty of predicting FDA
filings and approvals, consumer acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, IMPAX's ability to
successfully develop and commercialize pharmaceutical products, IMPAX's
reliance on key strategic alliances, the uncertainty of patent litigation, the
availability of raw materials, the regulatory environment, dependence on patent
and other protection for innovative products, exposure to product liability
claims, fluctuations in operating results and other risks detailed from time to
time in IMPAX's filings with the Securities and Exchange Commission.
Forward-looking statements speak only as to the date on which they are made,
and IMPAX undertakes no obligation to update publicly or revise any
forward-looking statement, regardless of whether new information becomes
available, future developments occur or otherwise.

    CONTACT: IMPAX Laboratories, Inc.
             Barry R. Edwards, 215-933-0323 Ext. 4360
             or
             Larry Hsu, 510-476-2000 Ext. 1111
             www.impaxlabs.com
             or
             Lippert/Heilshorn & Associates, Inc.
             Kim Sutton Golodetz, 212-838-3777 (Investor Relations)
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100
             bvoss@lhai.com
             www.lhai.com